
Sign up to save your podcasts
Or


Envato, the Australian tech company, has been sold for over $370 million, in one of the largest tech exits in Australian history.
Novo Nordisk, the pharmaceutical company behind diabetes slash weight loss drug Ozempic, drops price amidst competition.
Media giant Paramount Global is in talks with Sony over a potential buyout that could be worth $39 billion…after a failed negotiation with another potential buyer.
—
Build the financial wellbeing of your team with Flux at Work: https://bit.ly/fluxatwork
Download the free app (App Store): http://bit.ly/FluxAppStore
Download the free app (Google Play): http://bit.ly/FluxappGooglePlay
Daily newsletter: https://bit.ly/fluxnewsletter
Flux on Instagram: http://bit.ly/fluxinsta
Flux on TikTok: https://www.tiktok.com/@flux.finance
—-
The content in this podcast reflects the views and opinions of the hosts, and is intended for personal and not commercial use. We do not represent or endorse the accuracy or reliability of any opinion, statement or other information provided or distributed in these episodes.
See omnystudio.com/listener for privacy information.
By Flux5
1212 ratings
Envato, the Australian tech company, has been sold for over $370 million, in one of the largest tech exits in Australian history.
Novo Nordisk, the pharmaceutical company behind diabetes slash weight loss drug Ozempic, drops price amidst competition.
Media giant Paramount Global is in talks with Sony over a potential buyout that could be worth $39 billion…after a failed negotiation with another potential buyer.
—
Build the financial wellbeing of your team with Flux at Work: https://bit.ly/fluxatwork
Download the free app (App Store): http://bit.ly/FluxAppStore
Download the free app (Google Play): http://bit.ly/FluxappGooglePlay
Daily newsletter: https://bit.ly/fluxnewsletter
Flux on Instagram: http://bit.ly/fluxinsta
Flux on TikTok: https://www.tiktok.com/@flux.finance
—-
The content in this podcast reflects the views and opinions of the hosts, and is intended for personal and not commercial use. We do not represent or endorse the accuracy or reliability of any opinion, statement or other information provided or distributed in these episodes.
See omnystudio.com/listener for privacy information.

6 Listeners

28 Listeners

41 Listeners

0 Listeners

4 Listeners

48 Listeners

147 Listeners

14 Listeners

65 Listeners

83 Listeners

123 Listeners

16 Listeners

5 Listeners

5 Listeners

45 Listeners

9 Listeners

9 Listeners

30 Listeners

290 Listeners

36 Listeners

2 Listeners

35 Listeners

33 Listeners

24 Listeners

23 Listeners

54 Listeners

0 Listeners

1 Listeners

3 Listeners

0 Listeners

0 Listeners

0 Listeners

0 Listeners

4 Listeners